Cargando…

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer

Detalles Bibliográficos
Autores principales:	Rocconi, Rodney P., Stanbery, Laura, Tang, Min, Madeira da Silva, Luciana, Walter, Adam, Monk, Bradley J., Herzog, Thomas J., Coleman, Robert L., Manning, Luisa, Wallraven, Gladice, Horvath, Staci, Bognar, Ernest, Senzer, Neil, Brun, Scott, Nemunaitis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163222/ http://dx.doi.org/10.1038/s43856-023-00290-0

Ejemplares similares

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
por: Rocconi, Rodney P., et al.
Publicado: (2021)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022)

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
por: Oh, Johnathan, et al.
Publicado: (2020)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
por: Barve, Vedin, et al.
Publicado: (2021)

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
por: Anderson, Peter, et al.
Publicado: (2023)

1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
por: Jay, C., et al.
Publicado: (2020)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
por: Nemunaitis, John, et al.
Publicado: (2023)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
por: Morand, Susan, et al.
Publicado: (2020)

Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance
por: Enjyoji, Keiichi, et al.
Publicado: (2008)

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
por: Ghisoli, Maurizio, et al.
Publicado: (2015)

The ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing cholangitis
por: Peng, Zhen‐Wei, et al.
Publicado: (2017)

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
por: Sliheet, Elyssa, et al.
Publicado: (2021)

Comments on Cui Q‐Q et al: “Hippocampal CD 39/ENTPD 1 promotes mouse depression‐like behavior …”
por: Zimmermann, Herbert
Publicado: (2020)

Association of the ENPP1/ENTPD1 Polymorphisms in Hemodialysis Patients
por: Zhang, Xi, et al.
Publicado: (2021)

Emerging technologies for the genomic analysis of cancer
por: Nemunaitis, John, et al.
Publicado: (2009)

Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
por: Chiu, David Kung-Chun, et al.
Publicado: (2017)

Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials
por: Zhang, Yixin, et al.
Publicado: (2022)

Letter to the editor: Does Dicer Expression Affect shRNA processing?
por: Senzer, Neil, et al.
Publicado: (2009)

Identification of ENTPD8 and cytidine in pancreatic cancer by metabolomic and transcriptomic conjoint analysis
por: An, Yong, et al.
Publicado: (2018)

Identifying small molecule probes of ENTPD5 through high throughput screening
por: Durst, Matthew A., et al.
Publicado: (2019)

Functional ENTPD1 Polymorphisms in African Americans With Diabetes and End-Stage Renal Disease
por: Friedman, David J., et al.
Publicado: (2009)

Limited TCR repertoire and ENTPD1 dysregulation mark late-stage COVID-19
por: Wang, Na, et al.
Publicado: (2021)

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
por: Simmons, Olivia, et al.
Publicado: (2012)

Yeast model identifies ENTPD6 as a potential non-obstructive azoospermia pathogenic gene
por: Wang, Qian, et al.
Publicado: (2015)

Deletion of ENTPD3 does not impair nucleotide hydrolysis in primary somatosensory neurons or spinal cord
por: McCoy, Eric, et al.
Publicado: (2014)

ENTPD5 Induces Apoptosis in Lung Cancer Cells via Regulating Caspase 3 Expression
por: Xue, Yijun, et al.
Publicado: (2015)

Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021)

Procoagulant inhibitory properties of paclitaxel poliglumex
por: Nemunaitis, John, et al.
Publicado: (2010)

The ENTPD5/mt-PCPH oncoprotein is a catalytically inactive member of the ectonucleoside triphosphate diphosphohydrolase family
por: MacCARTHY, CAITLIN M., et al.
Publicado: ( 201)

A novel circular RNA circENTPD7 contributes to glioblastoma progression by targeting ROS1
por: Zhu, Fei, et al.
Publicado: (2020)

ENTPD3 Marks Mature Stem Cell–Derived β-Cells Formed by Self-Aggregation In Vitro
por: Docherty, Fiona M., et al.
Publicado: (2021)

The UDPase ENTPD5 regulates ER stress-associated renal injury by mediating protein N-glycosylation
por: Xu, Lifen, et al.
Publicado: (2023)

Systemic benefit of radiation therapy via abscopal effect
por: Craig, Daniel J., et al.
Publicado: (2022)

A new case of spastic paraplegia type 64 due to a missense mutation in the ENTPD1 gene
por: Mamelona, Jean, et al.
Publicado: (2019)

Endothelial Effects of Simultaneous Expression of Human HO-1, E5NT, and ENTPD1 in a Mouse
por: Mierzejewska, Paulina, et al.
Publicado: (2023)

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report
por: Fortman, Dylan, et al.
Publicado: (2019)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ju7bv46vsihgqq6qhk8g7immmt